Back to Cardiology
Cardiologyv2021Evidence-Based

Systematic Coronary Risk Evaluation 2 (SCORE2)

Predicts 10-year risk of cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) in patients aged 40-69 without prior cardiovascular disease or diabetes.

Clinical Input Parameters

years
Range: 40 — 69 years
mmHg
Range: 80 — 250 mmHg
mmol/L
Range: 2 — 12 mmol/L
mmol/L
Range: 0.5 — 3.5 mmol/L
Clinical Assessment
Awaiting Parameters
score2 risk
—%
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Systematic Coronary Risk Evaluation 2 (SCORE2) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

10-year risk = 1 - S0(10)^exp(x), where x = Σ[β × transformed_variables]. Variables are transformed: cage=(age-60)/5, csbp=(SBP-120)/20, ctot=(total_chol-6)/1, chdl=(HDL-1.3)/0.5. Coefficients vary by sex and risk region.

Clinical Pearls & Practice Notes

  • Only for patients aged 40-69 without prior CVD or diabetes
  • Risk thresholds are age-specific: <50 years vs 50-69 years
  • Risk regions: Low (Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, The Netherlands, UK), Moderate (Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia, Sweden), High (Albania, Armenia, Azerbaijan, Bosnia & Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan, Poland, Slovakia, Turkey), Very High (Algeria, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Republic of Moldova, Romania, Russian Federation, Serbia, Syria, North Macedonia, Tunisia, Ukraine, Uzbekistan)
  • Use SCORE2-OP for patients ≥70 years
  • Use SCORE2-Diabetes for patients with type 2 diabetes
  • Consider additional risk modifiers: family history, chronic kidney disease, mental disorders, HIV, inflammatory conditions

Evidence & Literature Citations

  1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
  2. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309.
  3. Hageman S, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K, de Vries T, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454.

Score Interpretation Ranges

Low to Moderate Risk (<50 years)0 – 2.5 pts

<2.5% 10-year risk

High Risk (<50 years) / Low to Moderate Risk (50-69 years)2.5 – 5 pts

2.5-5% 10-year risk

High Risk (<50 years) / High Risk (50-69 years)5 – 7.5 pts

5-7.5% 10-year risk

Very High Risk (<50 years) / High Risk (50-69 years)7.5 – 10 pts

7.5-10% 10-year risk

Very High Risk10 – 100 pts

≥10% 10-year risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.